A Controlled, Two-Arm, Parallel Group, Randomized Withdrawal Study to Assess the Safety and Efficacy of Hydromorphone Hydrochloride Delivered by Intrathecal Administration Using a Programmable Implantable Pump
Phase of Trial: Phase III
Latest Information Update: 04 May 2019
At a glance
- Drugs Hydromorphone (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Mallinckrodt Inc.; Piramal Critical Care
- 13 Apr 2018 Status changed from recruiting to completed.
- 28 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 28 Mar 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Sep 2017.